<?xml version='1.0' encoding='utf-8'?>
<document id="29996660"><sentence text="Associations Between PFA-Measured Aspirin Resistance, Platelet Count, Renal Function, and Angiotensin Receptor Blockers."><entity charOffset="90-101" id="DDI-PubMed.29996660.s1.e0" text="Angiotensin" /></sentence><sentence text="Aspirin resistance is used to describe patients who are undergoing aspirin therapy but fail for the inhibition of thromboxane biosynthesis in platelets"><entity charOffset="0-7" id="DDI-PubMed.29996660.s2.e0" text="Aspirin" /><entity charOffset="67-74" id="DDI-PubMed.29996660.s2.e1" text="aspirin" /><entity charOffset="114-125" id="DDI-PubMed.29996660.s2.e2" text="thromboxane" /><pair ddi="false" e1="DDI-PubMed.29996660.s2.e0" e2="DDI-PubMed.29996660.s2.e0" /><pair ddi="false" e1="DDI-PubMed.29996660.s2.e0" e2="DDI-PubMed.29996660.s2.e1" /><pair ddi="false" e1="DDI-PubMed.29996660.s2.e0" e2="DDI-PubMed.29996660.s2.e2" /><pair ddi="false" e1="DDI-PubMed.29996660.s2.e1" e2="DDI-PubMed.29996660.s2.e1" /><pair ddi="false" e1="DDI-PubMed.29996660.s2.e1" e2="DDI-PubMed.29996660.s2.e2" /></sentence><sentence text=" Although the true mechanism is unclear, drug-drug interaction remains a possible factor" /><sentence text=" The study aimed to determine whether there was association between aspirin resistance and the concomitant cardiovascular medication"><entity charOffset="68-75" id="DDI-PubMed.29996660.s4.e0" text="aspirin" /></sentence><sentence text=" Using the Platelet Function Analyzer-100 system, aspirin resistance was evaluated in aspirin-treated patients from the outpatient department"><entity charOffset="50-57" id="DDI-PubMed.29996660.s5.e0" text="aspirin" /><entity charOffset="86-93" id="DDI-PubMed.29996660.s5.e1" text="aspirin" /><pair ddi="false" e1="DDI-PubMed.29996660.s5.e0" e2="DDI-PubMed.29996660.s5.e0" /><pair ddi="false" e1="DDI-PubMed.29996660.s5.e0" e2="DDI-PubMed.29996660.s5.e1" /></sentence><sentence text=" The associations between aspirin resistance and their concomitant common cardiovascular medication were analyzed"><entity charOffset="26-33" id="DDI-PubMed.29996660.s6.e0" text="aspirin" /></sentence><sentence text=" Aspirin resistance was prevalent in 147 (17"><entity charOffset="1-8" id="DDI-PubMed.29996660.s7.e0" text="Aspirin" /></sentence><sentence text="7%) of 831 patients" /><sentence text=" Concomitant angiotensin receptor blocker (ARB) treatment and low platelet count were associated with aspirin response ( P = "><entity charOffset="102-109" id="DDI-PubMed.29996660.s9.e0" text="aspirin" /></sentence><sentence text="04, " /><sentence text="02, respectively)" /><sentence text=" Multivariate logistic regression analysis results showed an association between aspirin response and ARB therapy (adjusted odds ratio [OR] 1"><entity charOffset="81-88" id="DDI-PubMed.29996660.s12.e0" text="aspirin" /></sentence><sentence text="48; 95% confidence interval, CI: 1" /><sentence text="08-2" /><sentence text="18)" /><sentence text=" And the association was blunted when platelet count was considered (adjusted OR 1" /><sentence text="43, 95% CI: 0" /><sentence text="92-2" /><sentence text="23)" /><sentence text=" In ARB-treated patients, increased creatinine and decreased hematocrit laboratory data increased the risk of aspirin resistance ( P = "><entity charOffset="36-46" id="DDI-PubMed.29996660.s20.e0" text="creatinine" /><entity charOffset="110-117" id="DDI-PubMed.29996660.s20.e1" text="aspirin" /><pair ddi="false" e1="DDI-PubMed.29996660.s20.e0" e2="DDI-PubMed.29996660.s20.e0" /><pair ddi="false" e1="DDI-PubMed.29996660.s20.e0" e2="DDI-PubMed.29996660.s20.e1" /></sentence><sentence text="02, " /><sentence text="04, respectively), and the effect of platelet count on aspirin resistance was diminished by ARB therapy"><entity charOffset="55-62" id="DDI-PubMed.29996660.s22.e0" text="aspirin" /></sentence><sentence text=" Concomitant ARB treatment in aspirin-treated patients decreased the risk of aspirin resistance, and the effect was dependent on low platelet count"><entity charOffset="30-37" id="DDI-PubMed.29996660.s23.e0" text="aspirin" /><entity charOffset="77-84" id="DDI-PubMed.29996660.s23.e1" text="aspirin" /><pair ddi="false" e1="DDI-PubMed.29996660.s23.e0" e2="DDI-PubMed.29996660.s23.e0" /><pair ddi="false" e1="DDI-PubMed.29996660.s23.e0" e2="DDI-PubMed.29996660.s23.e1" /></sentence><sentence text=" In ARB-treated patients, increased creatinine and decreased hematocrit data increased the risk of aspirin resistance"><entity charOffset="36-46" id="DDI-PubMed.29996660.s24.e0" text="creatinine" /><entity charOffset="99-106" id="DDI-PubMed.29996660.s24.e1" text="aspirin" /><pair ddi="false" e1="DDI-PubMed.29996660.s24.e0" e2="DDI-PubMed.29996660.s24.e0" /><pair ddi="false" e1="DDI-PubMed.29996660.s24.e0" e2="DDI-PubMed.29996660.s24.e1" /></sentence><sentence text=" In addition, the effect of platelet count on aspirin resistance was diminished by ARB treatment"><entity charOffset="46-53" id="DDI-PubMed.29996660.s25.e0" text="aspirin" /></sentence><sentence text="" /></document>